Regular insulin added to TPN bag — Competitive Intelligence Brief

Regular insulin added to TPN bag (Regular insulin added to TPN bag) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (short-acting). Area: Endocrinology/Metabolic.

marketed Insulin (short-acting) Insulin receptor Endocrinology/Metabolic Small molecule

Target snapshot

Regular insulin added to TPN bag (Regular insulin added to TPN bag) — Fundación Pública Andaluza Progreso y Salud. Regular insulin lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism in patients receiving total parenteral nutrition.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Regular insulin added to TPN bag TARGET	Regular insulin added to TPN bag	Fundación Pública Andaluza Progreso y Salud	marketed	Insulin (short-acting)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (short-acting) class)

1. Fundación Pública Andaluza Progreso y Salud · 1 drug in this class
2. HaEmek Medical Center, Israel · 1 drug in this class
3. The University of Texas Medical Branch, Galveston · 1 drug in this class